Overview

Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Kansas Medical Center
Treatments:
SR 142801